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Many proteoforms – arising from alternative splicing, post-translational modifications
(PTMs), or paralogous genes – have distinct biological functions, such as histone PTM prote-
oforms. However, their quantification by existing bottom-up mass–spectrometry (MS) meth-
ods is undermined by peptide-specific biases. To avoid these biases, we developed and im-
plemented a first-principles model (HIquant) for quantifying proteoform stoichiometries.
We characterized when MS data allow inferring proteoform stoichiometries by HIquant,
derived an algorithm for optimal inference, and demonstrated experimentally high accu-
racy in quantifying fractional PTM occupancy without using external standards, even in
the challenging case of the histone modification code. A HIquant server is implemented at:
https://web.northeastern.edu/slavov/2014 HIquant/
Alternative mRNAs splicing and post-translational modifications (PTMs) produce multiple
protein isoforms per gene, termed proteoforms1. Furthermore, protein isoforms can be produced
by distinct but highly homologous open reading frames, i.e., paralogous genes. Despite having
similar sequence, proteoforms and protein isoforms often have distinct, even opposite biological
functions2. For examples: (i) some Bcl-x isoforms promote apoptosis while other Bcl-x isoforms
inhibit apoptosis3; (ii) the methylation of histone 3 can cause either transcriptional activation (ly-
sine 4) or repression (lysine 9) depending on the modified lysine4; and (iii) pyruvate kinase iso-
forms have different metabolic regulation, activities, and roles in aerobic glycolysis5–7.
Understanding such systems demands quantifying proteoform abundances. This demand has
motivated the development of external standards that can afford high accuracy even for complex
proteoforms8. However, their wider use has been limited by expense and applied only to special
cases that allow chemical modification of cell lysates, e.g., phosphorylation9 and acetylation10,11.
In the absence of external standards, the quantification of complex proteoform stoichiometries re-
mains very challenging because the ratios between proteoform-specific peptides do not necessarily
reflect the ratios between the corresponding proteoforms12; precursor ion areas corresponding to
the same phospho-site in the same sample can differ over 100-fold depending on the choice of pro-
tease13. This discrepancy is because a measured peptide level (precursor ion area) depends not only
on the abundance of the corresponding protein(s) but also on extraneous factors including protein
digestion, peptide ionization efficiency, the presence of other co-eluting peptides, and chromato-
graphic aberrations13–15. These extraneous factors break the equivalence between the abundance of
a peptide and its precursor ion area and thus make protein quantification much more challenging
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than DNA quantification by sequencing. This problem is compounded when PTM peptides have
been enriched, and thus their intensities scaled by unknown enrichment-dependent factors.
To infer proteoform stoichiometry, we use a simple model that is illustrated in Fig. 1a with
proteoforms of histone H3 and in Supplementary Fig. 1 with paralogous ribosomal proteins and
phospho-proteoforms of pyruvate dehydrogenase. HIquant explicitly models peptide levels mea-
sured across conditions as a superposition of the levels of the proteins from which the peptides
originate, Fig. 1a. In this model, shared peptides serve as indispensable internal standards; they
couple the equations for different peptides and thus make possible estimating stoichiometries be-
tween homologous proteins and proteoforms. The simple example in Fig. 1a generalizes to any
number of proteins / proteoforms (M) and any number of conditions greater than 1 (N > 1) as the
system in Fig. 1b shows. HIquant solves this system and infers the protein levels (P) independently
from the extraneous noise (Z; coming from protein-digestion, peptide-ionization differences, sam-
ple loss during enrichment, and even coisolation interference); Z is also inferred as part of the
solution and discarded. A related superposition model has been used before with peptides quan-
tified at one condition16. However for a single condition, the model cannot quantify the proteins
independently from the nuisance Z since all problems described by system 1 in Fig. 1 are under-
determined, i.e., have infinite number of solutions (Proof 1; Supplemental Information). Thus,
for a single condition, the model cannot take advantage of the robust corresponding-ion pairs, i.e.,
ratios between ions with the same chemical composition. In contrast, HIquant infers ratios across
proteins and their PTMs solely from the corresponding-ion ratios. This is possible because when
N > 1, the system in Fig. 1b often has a unique solution up to a single scaling constant, even when
all peptides are shared, e.g., the problem defined by the design matrix in Supplementary Fig. 1c.
We characterize the conditions under which HIquant has a unique solution for the abundances
of individual proteoforms and derive algorithms that use convex–optimization to find the optimal
solution given the data; see17 and Supplemental Information.
Our model (Fig. 1b) aims to make proteoform quantification insensitive to many systematic
biases. For example, incomplete cleavage of a peptide, e.g., only 5% of the peptide is released
during enzyme digestion, is fully absorbed into the corresponding nuisance and does not affect
inferred protein levels as long as the cleavage is 5% for all conditions/samples. Analogously, if
coisolation interference compresses the fold-changes of a peptide, the systematic component of the
compression is fully absorbed by the nuisances. Unlike systematic biases, random noise in the data
is not absorbed by the nuisances; it can degrade the quality of the inference. In order to assess the
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reliability of the inferred proteoform abundances, HIquant carefully evaluates the inference and
assigns confidence levels. The evaluation uses inference features, such as fraction of explained
variance, eigenvalue spectrum spacing and noise sensitivity; see Supplemental Information.
We sought to experimentally evaluate HIquant’s ability to infer the proteoform stoichiometry
in samples for which stoichiometry is accurately determined by other methods. The first method
included creating and mixing proteoforms. The second method included quantifying histone H3
proteoforms relative to heavy peptide standards with predetermined abundances.
We aimed to create proteoform mixtures with known stoichiometries so that they can be used
to assess the accuracy of stoichiometries inferred by HIquant. To this end, the dynamic universal
proteomics standard (UPS2) was digested, and the peptides split into two equal parts, A and B. In
part A, cysteines were covalently modified with iodoacetamide, and in part B with vinylpyridine,
Fig. 2a. We mixed part A and B in predefined ratios (n) and spiked each mixing ratio into an yeast
sample. All samples were labeled with TMT, and the relative peptide levels quantified from the
reporter ions at the MS2 level.
These alkylated UPS proteoforms have mostly shared peptides (peptides not containing cys-
teine) and a few unique peptides (peptides containing cysteine). HIquant modeled the relative
levels of these peptides as shown in Fig. 1 and solved the model to infer the stoichiometries of the
alkylated proteoforms (nˆ), which should correspond to the mixing ratios. A comparison between
the actual mixing ratios (n) with the inferred ratios (nˆ) demonstrates a median error below 10 %
for ratios inferred by HIquant and a substantially larger error for the ratios between precursor ion
areas of unique peptides (Fig. 2b,c); see Supplemental Information.
Next, we sought to evaluate the ability of HIquant to infer stoichiometries of more complex
PTM proteoforms, those of histone H3. This system allows rigorous quantification of endogenous
proteoform stoichiometries by a previously developed external standards (MasterMix) with known
concentrations8. For the test, we used peptides quantified by selective reaction monitoring (SRM)
across 7 perturbations. Fractional site occupancies were either estimated based on the external
standards or inferred by HIquant only from the relative levels of the indigenous peptides, without
using the MasterMix concentrations. The good agreement between these estimates (Fig. 3) val-
idates the ability of HIquant to infer fractional site occupancy even when the same site may be
modified by different PTMs. The estimates from the external standards and from HIquant are very
close but also show some systematic deviations. Those deviations may arise due to incomplete
protein digestion that is hard to control for with peptide standards, measurement noise corrupting
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the solution inferred by HIquant or proteforms not explicitly included in the model. The abun-
dances of some proteoforms with quantified peptides is over 1000 fold lower than the abundance
of the main proteoforms. They and their corresponding peptides were omitted from the HIquant
inference since their quantification requires unrealistically high accuracy of relative quantification;
see Supplemental Information and Discussion.
The idea of using ratios between chemically identical ions is a cornerstone of quantitative
proteomics18. It has been used for decades in the context of relative quantification of proteins
based on unique peptides19 and even applied to the special case of inferring phosphorylation cite
occupancy12. Our work expands and generalizes this idea to all peptides, to stoichiometries of
complex proteoforms, and to unlimited number of conditions. Crucially, HIquant allows accurate,
efficient, and numerically stable inference resulting in reliability estimates.
HIquant requires and depends upon accurate relative quantification. This limitation is largely
and increasingly mitigated by technological developments allowing accurate estimates of corresponding-
ion ratios. However, these technological developments on their own do not allow accurate esti-
mates of PTM site occupancy13. HIquant’s dependence on the accuracy of relative quantification
increases with increasing difference in the abundance of proteoforms. If the levels of two proteins
differ by more than 3-6 orders of magnitude, this difference is likely better inferred from the pre-
cursor ion areas of the unique peptides. The associated noise (due to variability in protein digestion
and ionization) is generally below 100 fold15 and thus smaller than the signal. HIquant’s utility is
particularly relevant when proteins and proteoforms have comparable abundances (within 10-100
fold difference) but distinct functions20 and thus accurate quantification is essential for quantifying
relatively small differences in abundance. Quantifying proteoforms is an exciting frontier essen-
tial for understanding post-transcriptional regulation21,22 and defining cell-types from single cell
proteomes23.
The general form of HIquant described in Fig. 1c indicates that HIquant is not limited to pro-
teoforms, even broadly defined. Rather, HIquant can be applied to any set of proteins sharing a
peptide. Here we emphasize the application to proteoforms because existing bottom-up methods
are better suited for quantifying the stoichiometry between proteins with low homology that gener-
ate many unique peptides. For proteins with multiple unique peptides, some of the peptide-specific
bias (from variation in protein-digestion and peptide-ionization efficiency) is likely to be averaged
out and reduced. However, this bias is a more serious problem for proteoforms with only one or
only a few unique peptides13. For such proteoforms, HIquant can allow estimating stoichiometries
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accurately using only ratios between chemically identical ions, and provide a measure of the inter-
nal reliability of its own estimated abundances.
Supplemental Information. Supplemental information includes Extended Experimental Proce-
dures, Mathematical Proofs, and Supplemental Figures can be found in the Supplemental Informa-
tion. The supplemental website for interactive data analysis can be found at:
https://web.northeastern.edu/slavov/2014 HIquant/
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Figure 1 | Model for inferring stoichiometries among proteoforms and paralogous proteins in-
dependently from peptide-specific biases. (a) One shared (x2) and three unique (x1, x3 and x4)
peptides of H3 proteoforms illustrate a very simple case of HIquant. HIquant models the peptide
levels measured across conditions (~x) as a supposition of the protein levels (~p), scaled by unknown
peptide–specific biases/nuisances (z). These coupled equations can be written in a matrix form
whose solution infers the methylation stoichiometry independently from the nuisances (z). (b)
The general form of the model for K proteoforms (or homologous proteins) with M peptides quan-
tified across N conditions can be formulated and solved. In many, albeit not all, cases an optimal
and unique solution can be found, even in the absence of unique peptides; see Supplementary
Fig. 1 and Supplemental Information.
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SH
4-vinylpyridine
Iodoacetamide
50%
48 UPS2
Proteins Cys Alkylation
S-VP
S-CM
50%
TMT-126 TMT-127 … TMT-131
UPS VP, μl 10 10 … 80
UPS CM,  μl 50 100 … 50
Lysate,  μl 100 100 … 100
Mix
Quantify by MS & infer
mixing ratios, i.e., VP/CM = n
n
1
a
10−1 100 101
10−1
100
101
UPS2 mixing ratios (n)
H
Iq
ua
nt
in
fe
rr
ed
ra
tio
s
(n
)
R 2 = 0 .997
ˆ
b
−3 −2 −1 0 1 2 3
0
500
1000
1500
2000
2500
3000
3500
4000
Error, log 2(
nˆ
n )
N
um
be
r
of
Pr
ot
ei
n
Ra
tio
s HIquant
ratios
Precursor ion
& RI ratios
c
Figure 2 | HIquant accurately quantifies ratios across alkylated proteoforms of a spiked-in stan-
dard. (a) Schematic diagram of a validation experiment. We prepared a gold standard of proteo-
forms from the dynamic universal proteomics standard (UPS2) whose cysteines were covalently
modified either with iodoacetamide or with vinylpyridine. Upon digestion, these modified UPS
proteins generate many shared peptides (peptides not containing cysteine) and a few unique pep-
tides (peptides containing cysteine). The modified UPS2 proteins were mixed with one another at
known ratios (n), mixed with yeast lysate, digested and quantified by MS. The proteoform ratios
that HIquant inferred from the MS data (nˆ) were compared to the mixing ratios. (b) The ratios
across the alkylated isoforms of UPS2 inferred by HIquant (nˆ, y-axis) accurately reflect the mixing
ratios (n, x-axis). (c) Comparison of the error in proteoform ratios inferred by HIquant and ratios
inferred from the precursor ion areas and the reporter ion (RI) ratios.
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Figure 3
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Figure 3 | HIquant accurately infers stoichiometries and confidence intervals across PTM site oc-
cupancies of histone 3. (a) Histone 3 peptides were quantified by SRM across 7 perturbations, and
the fractional site occupancies for K4 methylation estimated by two methods: Estimates inferred
by HIquant without using external standards are plotted against the corresponding estimates based
on MasterMix external standards with known concentrations8. Each marker shape corresponds to
the PTM site(s) shown in the legend; methylation is denoted with “me” and acetylation with “ac”
followed by the number of methyl/acetyl groups. (b) The validation method from (a) was extended
to another set of more complex fractional site occupancies on K9 methylation and K14 acetylation.
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Supplemental Figure 1
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Figure S1 | Model for inferring stoichiometries among proteoforms and paralogous proteins in-
dependently from peptide-specific biases. (a) One shared (x1) and two unique (x2 and x3) peptides
from the two paralogs of ribosomal proteins L6 illustrate the simplest case of HIquant. HIquant
models the peptide levels measured across two conditions (~x) as a supposition of the protein levels
(~p), scaled by unknown peptide–specific nuisances (z). These coupled equations can be writ-
ten in a matrix form whose solution infers the p1/p2 stoichiometry independently from the nui-
sances (z). (b) The shared and unique peptides of proteoforms (as illustrated by PDHA1 phospho-
proteoforms) can be modeled as in panel (a); (c) The matrix system from (a) generalizes to K
proteoforms (and homologous proteins) with M peptides quantified across N conditions. In many,
albeit not all, cases an optimal and unique solution can be found, even in the absence of unique
peptides. See Supplemental Information for details.
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